Trial reportObesity surgery2025
Ten‑Year Results of a Randomized Trial Comparing Banded Roux‑en‑Y Gastric Bypass to Sleeve Gastrectomy for Type 2 Diabetes and Weight Loss.
Trial report in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) are common bariatric procedures that are effective in treating type 2 diabetes (T2D) in patients with obesity. The addition of a silastic-ring (SR) to LRYGB may increase weight loss, reduce weight regain, and improve diabetes remission. Five and seven-year results from a prospective, randomized, parallel, two-arm, clinical trial at North Shore Hospital (Auckland, Aotearoa New Zealand) found that SR-LRYGB was superior to LSG for diabetes remission and weight loss following surgery, with acceptable complication rates. Results on longer-term outcomes are still emerging in the literature.
methodsA 10-year analysis was conducted on 114 patients with T2D who underwent SR-LRYGB or LSG. The primary outcome was diabetes remission assessed at 10 years. Secondary outcomes included percentage total body weight loss (%TWL) and complications.
resultsOf 114 patients randomized to either SR-LRYGB or LSG, 10 years after surgery, diabetes remission was seen in 15/49 (30.6%) after SR-LRYGB and 7/40 (17.5%) after LSG (adjusted OR 3.3; 95% confidence interval (CI) 1.0, 10.6; p = 0.042). Percentage total body weight loss was greater after SR-LRYGB than LSG (27.2% vs. 20.2%, absolute difference 7.0% 95% CI 2.2%, 11.8%; p = 0.005). Late minor complication rates were 28.6% after SR-LRYGB and 19.0% after LSG (absolute difference 9.6%, p = 0.226). Late major complication rates were 25.0% after SR-LRYGB and 31.0% after LSG (absolute difference 6.0%, p = 0.535).
conclusionsSR-LRYGB remains superior to LSG for diabetes remission and weight loss at 10 years following surgery. This study confirms long-term enhanced patient outcomes in patients undergoing SR-LRYGB when compared directly with LSG. This study adds to the mounting body of evidence that demonstrates sustained diabetes remission and weight loss in patients undergoing SR-LRYGB.
Indexed as
Identifiers
41144146What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.